CRBN and plasma cell myeloma: For example, a phase I/II trial (NCT06050512) evaluated the efficacy of the novel E3 ubiquitin ligase Cereblon (CRBN) modulator Mezigdomide combined with isazomib and dexamethasone in the treatment of relapsed refractory multiple myeloma (RRMM).